MARKET

INMB

INMB

Inmune Bio Inc
NASDAQ
1.940
+0.150
+8.38%
After Hours: 1.900 -0.04 -2.06% 19:50 07/10 EDT
OPEN
1.790
PREV CLOSE
1.790
HIGH
1.970
LOW
1.740
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
3.244
52 WEEK LOW
1.090
MARKET CAP
51.58M
P/E (TTM)
-1.1449
1D
5D
1M
3M
1Y
5Y
1D
Strengthening XPro1595 Data and De-Risked Registrational Path Support Buy Rating on INmune Bio with Unchanged $8 Price Target
TipRanks · 1d ago
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal
NASDAQ · 1d ago
INmune Bio Presents Positive Phase 2 Imaging Data For XPro In Early Alzheimer's Disease At AAIC 2026
NASDAQ · 2d ago
INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAIC
Benzinga · 2d ago
INmune Bio says Phase 2 XPro trial shows significant Week 24 MRI myelin benefit in early Alzheimer’s patients
PUBT · 2d ago
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
Barchart · 2d ago
Weekly Report: what happened at INMB last week (0629-0703)?
Weekly Report · 5d ago
INmune Bio Executes Warrant Inducement and Extension Agreement
TipRanks · 07/01 11:50
More
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Webull offers INmune Bio Inc stock information, including NASDAQ: INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.